CCM
PTLA

Cupps Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Cupps Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-97,090
Closed -$5M – 227
2015
Q4 		$5M Buy
97,090
+13,340
+16% +$647K 0.7% 56
2015
Q3 		$3.57M Buy
+83,750
New +$4.04M 0.47% 71

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cupps Capital Management's PTLA Position: Q1 2016 in Review

Cupps Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 97,090 shares — an estimated $5M sold.

Cupps Capital Management first reported a position in PTLA in Q3 2015 and held it in 2 quarters. The position peaked at $5M in Q4 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

  • Cupps Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Cupps Capital Management sold 97,090 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $5M.
  • Cupps Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Cupps Capital Management's Portola Pharmaceuticals, Inc. position peaked at $5M in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on Cupps Capital Management's 13F filing for Q1 2016, filed 12 May 2016.